Benralizumab and the integrated management of co‐morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps

Abstract Background Type 2 (T2) inflammation, characterized by blood and airway eosinophilia, underlies severe eosinophilic asthma (SEA) and chronic rhinosinusitis with nasal polyps (CRSwNP). In line with the Global Airways theory, SEA and CRSwNP frequently co‐occur, creating a multimorbid phenotype...

Full description

Bibliographic Details
Published in:Clinical and Translational Allergy
Main Authors: Joaquim Mullol, Maria D'Amato, Eugenio deCorso, Joseph K. Han, Jody Tversky
Format: Article
Language:English
Published: Wiley 2025-04-01
Subjects:
benralizumab
biologics
CRSwNP
eosinophilia
severe eosinophilic asthma
Online Access:https://doi.org/10.1002/clt2.70051

Internet

https://doi.org/10.1002/clt2.70051

Similar Items